CANY
MGNX icon

Caxton Associates (New York)’s MacroGenics MGNX Stock Holding History

Caxton Associates (New York)’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,562
Closed -$111K – 537
2023
Q4 		$111K Buy
+11,562
New +$79.9K 0.01% 442
2023
Q3 		– Sell
-13,838
Closed -$74K – 538
2023
Q2 		$74K Sell
13,838
-106,930
-89% -$660K 0.01% 465
2023
Q1 		$866K Sell
120,768
-70,589
-37% -$425K 0.13% 172
2022
Q4 		$1.28M Sell
191,357
-92,031
-32% -$505K 0.09% 80
2022
Q3 		$981K Buy
283,388
+265,779
+1,509% +$1.02M 0.13% 120
2022
Q2 		$52K Buy
+17,609
New +$92.6K 0.01% 531

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Caxton Associates (New York)'s MGNX Position: Q1 2024 in Review

Caxton Associates (New York) sold out of MacroGenics (MGNX) in Q1 2024, closing a stake of 11,562 shares — an estimated $111K sold.

Caxton Associates (New York) first reported a position in MGNX in Q2 2022 and held it in 6 quarters. The position peaked at $1.28M in Q4 2022. 163 funds tracked by Wall St. Rank hold MGNX as of Q1 2024.

  • Caxton Associates (New York) reported no remaining MacroGenics position as of Q1 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 11,562 MacroGenics shares in Q1 2024, an estimated $111K.
  • Caxton Associates (New York) first reported a position in MacroGenics in Q2 2022 and held it in 6 quarters.
  • Caxton Associates (New York)'s MacroGenics position peaked at $1.28M in Q4 2022.
  • 163 funds tracked by Wall St. Rank held MacroGenics as of Q1 2024.

Based on Caxton Associates (New York)'s 13F filing for Q1 2024, filed 15 May 2024.